Lv4
494 积分 2024-08-15 加入
Bispecific antibodies: a mechanistic review of the pipeline
15天前
已完结
PL02.12 Ivonescimab vs Placebo Plus Chemo, Phase 3 in Patients with EGFR+ NSCLC Progressed with 3rd gen EGFR-TKI Treatment: HARMONi
15天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
15天前
已完结
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
15天前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
15天前
已完结
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
15天前
已完结
Engineering antibodies for conditional activity in the solid tumor microenvironment
16天前
已完结
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
23天前
已完结
Laboratory data in healthy volunteers: reference values, reference changes, screening and laboratory adverse event limits in Phase I clinical trials
1个月前
已完结
466PEffective use of CD19xCD3 T-cell engager blinatumomab in refractory myasthenia gravis
1个月前
已完结
皖公网安备34019202002308
